US study of Artelon® Tissue Reinforcement in repair of rotator cuff tears published

Dr Thomas Marberry at Tulsa Bone & Joint Associates, Tulsa, Oklahoma, USA, has published a study on challenging rotator cuff tears. The study demonstrates a beneficial outcome from the use of Artelon® Tissue Reinforcement (ATR).

The tears are graded as large or massive and the patients selected for the study had poor tissue quality, which meant that it was difficult to achieve a lasting repair with suturing alone. The repair was reinforced with ATR, 17 patients were treated and followed up after three, six and 12 months. Post-operatively, the patients suffered considerably less pain, showed improved mobility and could return to their daily activities.

Västra Frölunda. September 18, 2012
Kjell Thörnbring

   

For further information, please contact:
Kjell Thörnbring, CEO
E-mail: kjell.thornbring@artimplant.com
Telephone:  +46 703 11 90 25

Further information at www.artimplant.com where one also can subscribe to future press releases; www.artimplant.com/investors-media/subscribe-to-press-releases.html

   

Artimplant
Artimplant is a biomaterials company focused on solutions to problems in orthopedic. We restore health through the development, production and marketing of degradable implants that regenerate body functions and improve quality of life. Our products, made from Artelon®, meet unmet clinical needs and are marketed in a growing number of therapy areas. Artimplant produces implants for treatment of osteoarthritis in hands and feet, for shoulder and other soft tissue injuries.

Artimplant is a public company listed on the OMX Nordic Exchange Stockholm in the Small Cap segment and in the healthcare sector.

Forward-looking statements
This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.
        

This is information which Artimplant shall make public pursuant to the Swedish Financial Instruments Act and the Swedish Securities Exchange and Clearing Operations Act and/or stock market agreements. Information was made available for publication on September 18, 2012 at 3 PM (Swedish time).